Advancing iPSC-Derived Ocular Cell Therapies to Improve Vision
3:40 pm - Wednesday 9th September 2026
- Reviewing pipelines with iPSC-derived retinal cell replacement, focusing on preclinical engraftment, structural preservation, and early clinical functional readouts
- Defining meaningful visual endpoints, durability markers and safety criteria that demonstrate clinical benefit and support the move from early-phase studies toward larger efficacy trials
